HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

zinc deuteroporphyrin IX 2,4-bis(glycol)

structure given in first source

Also Known As:

Zn-DT-2,4-G; ZnBG

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Stevenson, David K: 5 articles (08/2012 - 10/2002)
2.	Vreman, Hendrik J: 5 articles (08/2012 - 10/2002)
3.	Wong, Ronald J: 5 articles (08/2012 - 10/2002)
4.	Zhao, Hui: 3 articles (08/2012 - 10/2002)
5.	Contag, Christopher H: 3 articles (05/2006 - 10/2002)
6.	Kalish, Flora S: 2 articles (08/2012 - 11/2011)
7.	Schulz, Stephanie: 2 articles (08/2012 - 11/2011)
8.	Contag, Pamela R: 2 articles (07/2003 - 10/2002)
9.	Hajdena-Dawson, Monica: 2 articles (07/2003 - 10/2002)
10.	Zhang, Weisheng: 2 articles (07/2003 - 10/2002)

Related Diseases

1.	Neonatal Jaundice 10/01/2002 - "Among the known inhibitors of HO enzyme activity that were evaluated in this study, ZnBG did not significantly affect HO-1 transcription and therefore may be well suited for the prevention of neonatal jaundice." 01/01/1991 - "Zinc deuteroporphyrin IX 2,4-bis-glycol (ZnBG) is a potent inhibitor of heme oxygenase and may be useful in the prevention of neonatal jaundice. "
2.	Body Weight (Weight, Body) 11/01/2011 - "The I(50) of ZnBG was found to be 4.0 μmol/kg body weight (BW). " 12/01/1991 - "Furthermore, administration of ZnBG to 1-day-old neonatal rats caused mortality within 12 hours in light-exposed animals, with a lethal dose 50 of 23 microM/kg body weight." 12/01/1991 - "Administration of 4 mumole ZnBG/kg body weight to adult rats significantly reduced the total body carbon monoxide (CO) excretion, an index of bilirubin formation, from 1 to 6 hours posttreatment. " 05/01/2006 - "Adult HO-1-luc reporter mice were administered 30 micromol/kg body weight of tin mesoporphyrin (SnMP), zinc bis glycol deuteroporphyrin (ZnBG), or zinc protoporphyrin (ZnPP), or vehicle by oral gavage. "
3.	Neonatal Hyperbilirubinemia 11/01/2011 - "We conclude that ZnBG may be an attractive compound for treating severe neonatal hyperbilirubinemia caused by hemolytic disease." 08/01/2012 - "Low doses of ZnBG (<3.75 μmol/kg) retained maximal HO inhibitory potency without photosensitizing effects, and therefore are potentially useful in treating neonatal hyperbilirubinemia."
4.	Phototoxic Dermatitis (Phototoxicity) 08/01/2012 - "Phototoxicity of ZnBG was dependent on light source, emission spectrum, and irradiance. "
5.	Periodontal Pocket (Periodontal Pockets) 11/01/2012 - "Based on the in vitro assessments using rBMSCs, the ZnBG-added PLA is considered to be of potential use in guiding active bone regeneration within the periodontal pocket."

Related Drugs and Biologics

1.	Enzymes
2.	Zinc
3.	deuteroporphyrin-IX
4.	Photosensitizing Agents (Photosensitizers)
5.	Heme Oxygenase (Decyclizing) (Heme Oxygenase)
6.	Carbon Monoxide
7.	Bilirubin
8.	tin mesoporphyrin
9.	zinc protoporphyrin

Related Therapies and Procedures

1.	Therapeutics